Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 28, 2013; 19(32): 5381-5384
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5381
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5381
Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease
Cristian Cerda, Miguel Bruguera, Albert Parés, Liver Unit, Institute of Digestive and Metabolic Diseases, Hospital Clínic, 08036 Barcelona, Spain
Cristian Cerda, Miguel Bruguera, Albert Parés, Department of Medicine, University of Barcelona, 08036 Barcelona, Spain
Author contributions: Bruguera M designed the study and wrote de report; Cerda C and Parés A contributed to data gathering and writing the report.
Correspondence to: Miguel Bruguera, Professor, Liver Unit, Institute of Digestive and Metabolic Diseases, Hospital Clínic, Villarroel 270, 08036 Barcelona, Spain. bruguera@clinic.ub.es
Telephone: +34-93-2275753 Fax: +34-93-2271779
Received: February 26, 2013
Revised: April 30, 2013
Accepted: June 5, 2013
Published online: August 28, 2013
Revised: April 30, 2013
Accepted: June 5, 2013
Published online: August 28, 2013
Core Tip
Core tip: A questionnaire was given to 151 consecutive patients with chronic liver disease of different etiology (mean age 59 years, 56.9% women) attended in an outpatient clinic with the aim of evaluating the frequency of consumption of these drugs and determine whether their use coincided with a worsening in liver function test results. Twenty-three patients (15.2%) recognized having taken products containing glucosamine or chondroitin sulfate previously or at the time of the questionnaire.